You are here

Home » Content

Olgu: DMPA ile Gebelik - Yöntem Başarısızlığı mı?

CASE REPORT: DMPA AND PREGNANCY - A METHOD FAILURE?

Journal Name:

  • Türkiye Aile Hekimliği Dergisi

Publication Year:

  • 2003

Key Words:

Keywords (Original Language):

Author Name
Abstract (2. Language): 
42 year old woman with G7P3L3C3 reported that she got pregnant although she had a DMPA injection 3 months ago and requested a legal abortion in our clinic. She claimed that she had her first DMPA injection 3 months ago in a family planning unit in another education and research hospital. She did not have any worries about not having her periods then on because she was told that this method is safe, highly effec¬tive and frequently causes amenorrhoea. When she applied to the family planning unit with subsequent complaints of nau¬sea and bloating, she was reassured that such symptoms were common in the first few months of injections. When she realized that her abdomen enlarged, she took a pregnancy self test kit which revealed positive. Then she applied to our Family Planning Unit in Haydarpaşa Numune Education and Research Hospital, with an unwanted pregnancy and a request of legal abortion. Her physical examination unveiled a 17 weeks pregnancy. When she was questioned, it was understood that she was not called for a check visit after her DMPA injection following her legal abortion 12 weeks ago. Conclusion: We concluded that all cases whom legal abor¬tions are performed must be reevaluated for the risk of unsuc¬cessful evacuations or complications. Although it seems as a method failure in the first place, it is obvious that the preg¬nancy was not terminated.
Bookmark/Search this post with
Abstract (Original Language): 
Olgu: 1961 doğumlu, G7P3Y3C3 olan Ş.K., 3 aylık korunma iğnesi kullandığı halde gebe kaldığını ve aldırmak istediğini söyleyerek Haydarpaşa Numune Hastanesi Aile Planlaması Üni-tesi'ne başvurdu. ilk kez 3 ay önce başka bir eğitim hastanesinin Aile Planlaması Merkezinde DMPA uygulanan olguya bu yöntemin çok güvenilir ve etkili bir koruma sağladığı, ancak adetten kesebileceği söylenmiş; bu nedenle adet görmediği için endişelenmemişti, bir kez de bulantı ve şişkinlik nedeniyle aynı merkeze başvurduğunda bunun ilk aylarda normal olduğu söylenmişti. Karnının büyümesi üzerine şüphelenerek gebelik testi yaptıran ve pozitif çıkması nedeniyle bize başvuran ol¬gumuz, gebeliğini sonlandırmak istediğini söyledi. Muayene ve USG ile 17 haftalık gebe olduğunu saptadığımız olgunun öyküsü derinleştirdiğimizde, kendisine 12 hafta önce yasal tahliye sonrası aynı gün DMPA yapıldığı ve kürtaj sonrası kontrole çağrılmadığı tespit edildi. Sonuç: Yasal tahliye yapılan tüm olguların gebeliğin devamı ya da komplikasyonların saptanabilmesi açısından kontrole çağı¬rılması gerektiği sonucuna vardık. ilk başta DMPA'ya bağlı yöntem başarısızlığı gibi görünen, ancak gebeliğin sonlandırı-lamaması nedeniyle gebeliğin devamı olan bu olgunun sunul¬masının uygun olduğunu düşünüyoruz.
FULL TEXT (PDF): 
PDF icon arastrmx_116859_7_pp_180-182.pdf
  • 4
180-182
  • Turkish

REFERENCES

References: 

1. Schwallie PC, Assenzo JR. Contraceptive use - efficacy studies utilizing medroxyprogesterone acetate administered as an intramuscular injection once every 90 days. Fertil Steril 1973; 24: 331.
2. Kaunitz AM. Long acting injectable contraception. Clin Obstet Gynecol 1989; 32: 356.
3. Kaunitz AM. Depot medroxyprogesterone acetate contraception and the risk of breast and gynecologic cancer. J Reprod Med 1996; 41(5 suppl):
419.
4. Klitsch M. Injectable hormones and regulatory controversy: An end to the long-running story? Fam Plann Perspect 1993; 25: 37.
5. Trussell J, Kost K. Contraceptive failure in the United States: A critical review of the literature. Stud Fam Plann 1987; 18: 237.
6. Trussell J, Vaughan B. Contraceptive failure, method-related discontinuation and resumption of use: Results from the 1995 National Survey of family growth. Fam Plann Perspect 1999; 31: 64.
7. Kaunitz AM. Long-acting contraceptive options. Int J Fertil 1996;
41:69.
8. Sapire KE. Depo-provera and carbamazepine (letter). B J Fam Plann
1990; 15: 130.
9. Burkman RT. (Ed) Update in Contraception Obstetric and Gynecology
Clinics of North America 2000; 27(4): 747.
10. Fotherby K, Benagiano G, Toppozada HK ve ark. A preliminary phar¬macological trial of the monthly injectable contraceptive Cycloprovera. Contraception 1982; 25: 261.
11. Winikoff B, Sivin I, Coyaji KJ ve ark. Safety, efficacy, and acceptabi¬lity of medical abortion in China, Cuba, and India: a comparative trial of mifepristone-misoprostol versus survical abortion. Am J Obstet Gynecol
1997; 176: 731-7.
12. Sciarra's Gynecology and Obstetrics. Ed. Sciarra JJ, Daly MJ, Zatunc-hi GI. Philadelphia, Harper and Row Publisher, 1984.
13. Hakim-Elahi E, Harold M, Tovell M. Complications of first trimester abortion: a report of 170.000 cases. Obstet Gynecol 1990; 76: 129.
14.
Ulusa
l Aile Planlaması Hizmet Rehberi Cilt 1 T.C. Sağlık Bakanlığı AÇ-SAP Genel Müdürlüğü 1996, 3. basım, Ankara.
15. American College of Obstetricians and Gynecologists: Contraceptives and congenital anomalies. ACOG Committee Opinion 124. Washington,
DC, ACOG, 1993.
16. Simpson JL. Mutagenicity and teratogenicity of injectable and implan-table progestins: Probable lack of effect. Long-Acting Contraceptive De¬livery Systems. Ed. Zatuchni GI, Goldsmith A, Shelton JD, Sciarra JJ. Philadelphia, Harper & Row, 1984; 334-361.
17. Simpson JJ, Philips OP. Spermicides, hormonal contraception and con¬genital malformations. Adv Contracept 1990; 6:141.
18. Kaunitz AM. Long-acting injectable contraception with depot med-roxyprogesterone acetate. Am J Obstet Gynecol 1994; 170: 1543-9.

Thank you for copying data from http://www.arastirmax.com